XML 70 R60.htm IDEA: XBRL DOCUMENT v3.23.3
Interest in joint venture - Summary of financial information in joint venture (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Disclosure of joint ventures [line items]            
Cash and cash equivalents $ 310,407 $ 380,860 $ 310,407 $ 380,860 $ 326,441 $ 466,544
Intangible assets 12,358 14,598 12,358 14,598 14,360  
Total liabilities (521,081)   (521,081)   (440,441)  
Operating expense 51,897 79,435 181,533 252,999    
Net loss (47,807) (50,608) (154,350) (131,643)    
Overland ADCT BioPharma            
Disclosure of joint ventures [line items]            
Cash and cash equivalents 9,238   9,238   19,261  
Prepaid and other current assets 364   364   2  
Intangible assets 49,249   49,249   49,249  
Total liabilities (3,553)   (3,553)   (3,062)  
Net assets 55,298   55,298   $ 65,450  
Operating expense 2,750 4,950 8,278 14,317    
Other expense (income) 126 (604) (1,057) (1,308)    
Other comprehensive loss (income) (157) 0 1,274 0    
Net loss $ 2,719 $ 4,346 $ 8,495 $ 13,009